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TNF-a and IFN-c Are Potential Inducers of
Fas-Mediated Keratinocyte Apoptosis through
Activation of Inducible Nitric Oxide Synthase
in Toxic Epidermal Necrolysis
Isabelle Viard-Leveugle1,2,5, Olivier Gaide2,5, Dragana Jankovic3, Laurence Feldmeyer3, Katrin Kerl3,
Chris Pickard4, Ste´phanie Roques2, Peter S. Friedmann4, Emmanuel Contassot3,6 and Lars E. French3,6
Toxic epidermal necrolysis (TEN) is a severe immune-mediated adverse cutaneous drug eruption characterized by
rapid and extensive epithelial cell death in the epidermis and mucosae. The molecular events leading to this
often fatal condition are only partially understood, but evidence suggests a dual mechanism implicating a ‘‘drug’’-
specific immune response on one side and the onset of target cell death by proapoptotic molecules including
FasL on the other side. Herein, we describe a potential molecular bridge between these two events that involves
inducible nitric oxide synthase (iNOS), which is highly upregulated in the skin of TEN patients. We show that
activated T cells secrete high amounts of tumor necrosis factor-a (TNF-a) and IFN-g, and that both cytokines lead
to increased expression and activity of keratinocyte iNOS. A similar observation has been made with drug-
specific T lymphocytes from a TEN patient exposed to the culprit drug. The resulting increase in nitric oxide
significantly upregulates keratinocyte FasL expression, resulting in Fas- and caspase-8-mediated keratinocyte cell
death. Taken together, our data suggest that T-lymphocyte activation by drugs in TEN patients may indirectly lead
to FasL-mediated keratinocyte apoptosis, via a molecular bridge involving TNF-a, IFN-g, and iNOS.
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INTRODUCTION
Toxic epidermal necrolysis (TEN), also called Lyell’s syn-
drome, is a severe muco-cutaneous adverse drug reaction
occurring at an estimated incidence of 0.4–1.2 cases per
million (Roujeau et al., 1990a, b) with an average mortality
ranging between 25 and 35%. The pathogenesis of the disease
is incompletely understood, and little is known about the
precise molecular mechanisms leading to the widespread
epidermal necrolysis observed in TEN (French, 2006).
The observations that (i) TEN recurrence is faster and more
severe if the patient is reexposed to the culprit drug (Paquet
et al., 2002), that (ii) drug-specific T cells are found in the skin
of TEN patients (Nassif et al., 2004a), and that (iii) patients
with certain HLA haplotypes bear a higher risk of developing
TEN when exposed to certain drugs (Chung et al., 2004;
Hung et al., 2005) strongly support a role of T-cell–mediated
immune responses in TEN pathogenesis. However, TEN has
also been documented in a pancytopenic patient (Paquet
et al., 2005b), and, moreover, few CD8þ cytotoxic T cells are
found in the epidermal infiltrate in the majority of cases.
Hence, it appears unlikely that lymphocytes alone induce a
rapid and massive keratinocyte apoptosis by a direct cell-
mediated cytotoxic effect (Roujeau et al., 1990a; Paul et al.,
1996). We have shown that during TEN keratinocytes strongly
upregulate their FasL surface expression, thus inducing
keratinocyte apoptosis by engaging constitutively expressed
Fas (Viard et al., 1998; Viard-Leveugle et al., 2003). Since
then, others have provided further evidence of the above
(Abe et al., 2003; Paquet et al., 2005a; Marzano et al., 2007;
Stur et al., 2007). However, the molecular events leading to
the upregulation of surface keratinocyte FasL during TEN
remain unknown.
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Nitric oxide (NO) is a small diffusible short-lived molecule,
generated by specific nitric oxide synthases (NOS), that has
pleiotropic effects including the ability to induce epidermis
keratinocyte apoptosis (Kim et al., 1999; Ormerod et al.,
1999). In TEN patient epidermis, Lerner et al. (2000) found it
to be significantly increased. The NOS in endothelial and
neuronal cells are constitutively expressed, whereas activation
of macrophages and other cells with proinflammatory
cytokines or lipopolysaccharide is required for the express-
ion of the inducible NOS (iNOS). These three isoforms are
detectable in the human skin (Shimizu et al., 1997; Bruch-
Gerharz et al., 1998). The amount of NO generated by iNOS
has been shown to be greater than the amount generated
by endothelial and neuronal NOS. Interestingly, iNOS is
upregulated in the epidermis of TEN patients (Lerner et al.,
2000) and is regulated in keratinocytes by IFN-g and tumor
necrosis factor-a (TNF-a) (Heck et al., 1992; Arany et al.,
1996), two cytokines that have been shown to be present at
high levels in blister fluids of TEN patients (Nassif et al.,
2004b; Gandhi et al., 2008). Moreover, exposure of
lymphoma cells to NO results in FasL upregulation and Fas-
mediated apoptosis (Villada et al., 1992; Correia et al., 1993;
Paquet et al., 1994; Chlichlia et al., 1998). We therefore
hypothesized that an iNOS–NO–FasL pathway may represent
a potential link between the immune activation and the
widespread keratinocyte apoptosis observed in TEN. Herein,
we provide evidence that activated T cells secrete large
amounts of TNF-a and IFN-g, which have the ability to induce
keratinocyte iNOS expression and NO production, with
subsequent FasL upregulation and Fas-mediated keratinocyte
apoptosis.
RESULTS
NO donor–mediated oxidative stress induces keratinocyte
surface FasL expression and Fas-mediated apoptosis
We observed that lesional skin of TEN patients shows high
levels of iNOS in keratinocytes, confirming previous observa-
tions (Lerner et al., 2000) (Figure 1a). Besides, the skin of TEN
patients was clearly distinguishable from the skin of macula-
papular rash patients with respect to iNOS mRNA expression.
Indeed, TEN patients expressed significantly higher levels of
iNOS (Figure 1b; n¼5). We then determined whether
keratinocytes exposed to high levels of NO upregulate FasL
and induce Fas-mediated apoptosis. The NO donors NOC18
and sodium nitroprusside (SNP) were added to the culture
medium of HaCaT cells, and cell-surface FasL expression was
analyzed by flow cytometry. FasL expression was induced
in NOC18 and SNP-exposed HaCaT cells compared with
untreated cells (Figure 1c). The mean fluorescence intensity
increased by 1.95±0.20 and 1.78±0.48, respectively, in
SNP- and NOC18-exposed cells as compared with control
(n¼ 3–10 experiments). Similar results were obtained with
primary keratinocytes (human interfollicular epidermal kerati-
nocytes; HEK, data not shown). This induction of FasL
expression occurred rapidly, as 20% of cells expressed cell-
surface FasL by 8 hours after NO-donor exposure.
To investigate whether FasL expression induced by NO
exposure was biologically active, we quantified apoptosis in
HaCaT cells exposed to NO donors. Both NOC18 and SNP
significantly induced apoptosis (60–70% apoptosis in exposed
HaCaT cells vs. 12% in unexposed cells) (Figure 1d). Similar
results have been observed in oral epithelial cells (Lee et al.,
2006). To rule out a Fas-independent toxic effect of NO
donors, we analyzed the effect of Fas–FasL signaling pathway
inhibitors. We found that NO donor–induced apoptosis was
inhibited by both the pan-caspase inhibitor ZVAD and
recombinant Fas:Fc (Figure 1d), demonstrating that most of
the HaCaT apoptosis involves FasL induction of caspase-
dependent Fas-mediated apoptosis. Effects of NO donors
on Fas expression on HaCaT cells were also investigated.
Although Fas expression was increased upon SNP exposure, it
was not significantly modified upon NOC18 exposure (data
not shown). Therefore, the increased apoptosis observed upon
SNP and NOC18 exposure was likely due to FasL upregula-
tion and did not require increased Fas expression. However,
to concentrate on the role of FasL, we used only NOC18 for
further investigation.
Taken together, our data suggest that NO release induces
apoptosis through FasL, not Fas, upregulation. This is in
agreement with results reported in Jurkat cells, showing that
glyceryl trinitrate, another NO donor, induces FasL but not Fas
expression (Chlichlia et al., 1998).
NO donors induce Fas/FasL-mediated apoptosis of basal-layer
keratinocytes
To determine whether large amounts of NO generated by NO
donors could have the potential to induce FasL expression and
Fas-mediated keratinocyte apoptosis in the human epidermis,
we used the EpiDerm in vitro–reconstituted epidermis as a
model. Immunohistochemical analysis clearly showed that
basal keratinocytes of NOC18-exposed EpiDerm coexpressed
FasL and active caspase-3. The exposure of EpiDerm to
NOC18 significantly increased the number of active cas-
pase-3-expressing keratinocytes as compared with vehicle
exposure (Figures 2a, vehicle/NOC18 vs. vehicle/vehicle).
To determine whether apoptosis was Fas mediated, we
used the caspase-8 inhibitor Z-IETD-FMK and the recombinant
Fas inhibitors Fas:Fc and Fas:Comp. Preincubation with
Z-IETD-FMK before NOC18 exposure completely inhibited
caspase-3 activation. No inhibition of apoptosis was observed
with Z-FA-FMK control molecule (Figures 2a and b). Fas:Fc
and Fas:Comp also significantly reduced the number of
apoptotic keratinocytes induced by NO exposure, whereas
the control-Fc recombinant protein had no effect (Figures 2a
and b).
These data demonstrate that NO-induced apoptosis in
human epidermal equivalent is mediated by caspase-8-depen-
dent Fas-signaling pathway activation. Interestingly, a signifi-
cant inhibition with intravenous immunoglobulin, containing
high amounts of anti-Fas antibodies (Viard et al., 1998), was
also observed (Figure 2a).
TNF-a and IFN-c synergize to induce iNOS, FasL expression, and
NO production in human keratinocytes
As high levels of IFN-g and TNF-a have been found in blister
fluids of TEN patients, and these cytokines have been reported
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to upregulate iNOS (Heck et al., 1992; Arany et al., 1996), we
investigated whether they could be a trigger for iNOS
expression, NO production, and FasL induction in human
keratinocytes. We also included IL-1b, another very potent
proinflammatory cytokine in our analyses. Indeed, quantitative
PCR analysis showed a 4.5-fold overexpression of iNOS in
keratinocytes treated with IL-1b, TNF-a, and IFN-g, compared
with untreated cells, and FasL overexpression was 4.7-fold
(Figure 3a).
Upon incubation with IFN-g, TNF-a, and IL-1b, in the
presence of the iNOS inhibitor L-NG-monomethyl-arginine
citrate (L-NMMA), the expression of both iNOS and FasL was
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Figure 1. Nitric oxide (NO) donors increase membrane FasL expression and cell apoptosis in keratinocytes. (a) Immunohistological detection of inducible nitric
oxide synthase (iNOS) and FasL in toxic epidermal necrolysis (TEN) and normal skin biopsies. Bar¼200mm. (b) Total RNA was extracted from lesional skin from
patients with maculo-papular rash (MPR, n¼ 10) or TEN (n¼5), and iNOS quantitative RT–PCR was performed (*Po0.01). (c) Cell-surface FasL expression
on keratinocytes by FACS analysis of HaCaT cells treated or not treated (Cont) with NO donors (SNP and NOC18). Results from one of four representative
experiments. SNP- and NOC18-induced keratinocyte apoptosis detected by Annexin-FITC labeling (d) was completely inhibited by ZVAD and Fas:Fc. Results from
one of four representative experiments. (e) Percentage of apoptotic keratinocytes (early plus late) in HaCaT cells treated or not treated (blank histogram) with ZVAD
(black histogram) or Fas:Fc (gray histogram) in addition of NO donors. Data shown are mean±standard deviation, n¼3.
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significantly decreased to 1.3- and 1.5-fold, respectively
(Figure 3b). Similar results were observed with 1,400W,
another iNOS inhibitor (data not shown). FACS analysis using
the NO-sensitive dye DAF–FM–DA as a surrogate marker of
NO production revealed that keratinocytes exposed to IFN-g
or, to a lesser extent, TNF-a significantly increased their NO
production (Figure 3c). IL-1b alone had no effect. The effect of
IFN-g could be potentiated by costimulation with TNF-a or, to
a lesser extent, IL-1b. Furthermore, combining these two very
potent proinflammatory cytokines, namely TNF-a and IL-1b,
had no additional effect over TNF-a alone (Figure 3c). In the
presence of L-NMMA, a specific iNOS inhibitor, NO induc-
tion by IFN-g and TNF-a was significantly reduced (Figure 3d,
58±12% inhibition). Similar results were obtained with two
other iNOS inhibitors, 1,400W and aminoguanidine (data not
shown). Taken together, these results suggest that IFN-g,
together with TNF-a, is a key inducer of iNOS activation,
followed by NO production and subsequent FasL expression
in keratinocytes.
Activated T-cell–derived products induce iNOS expression and
NO production in keratinocytes
Peripheral blood mononuclear cells (PBMCs) were activated
with anti-CD3 for 72 hours and filtered medium was trans-
ferred to HaCaT or HEK cultures. A strong induction of iNOS
mRNA was found in keratinocytes incubated with CD3-
activated PBMC-conditioned medium as compared with
medium from nonactivated PBMCs (Figures 4a and 5a). The
induction of iNOS mRNA was detected as of 8 hours
and peaked at 16 hours. In accordance with these results,
we found a higher NO production in keratinocytes exposed
to conditioned medium of CD3-activated PBMCs compared
with medium from nonactivated PBMCs. Furthermore, incu-
bation of keratinocytes with L-NMMA resulted in reduced
NO production, confirming that the observed fluorescence
shift is indeed the result of keratinocyte NO production
induced by conditioned medium of CD3-activated PBMCs
(Figure 4b). Largely similar results were observed upon
inhibition of iNOS with 1,400W and aminoguanidine (data
not shown).
To further investigate the hypothesis that drug-activated T
cells in patients with TEN may induce increased keratinocyte
NO production via the production of the proinflammatory
cytokines IFN-g- and TNF-a, we used conditioned medium
from drug-specific T-cell clones from a TEN patient on
keratinocytes. Interestingly, we found that these T-cell clones,
when stimulated with the culprit drug, secreted high levels of
TNF-a and IFN-g (Table 1), similar to those observed in CD3-
activated PBMCs, with a median increase over control non-
stimulated T-cell clones of 6,345 pg ml 1 ±4,190 for IFN-g
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and 160 pg ml1 ±200 for TNF-a. Keratinocytes exposed to
phenytoin-activated T-cell clone media also revealed signifi-
cantly increased NO production, when compared with med-
ium from nonstimulated T-cell clones (Figure 4c). This NO
production increase was observed with media of the 10
different phenytoin-activated T-cell clones tested, with a
6-fold average increase in keratinocyte NO production.
TNF-a and IFN-c induce iNOS mRNA expression, NO
production, and apoptosis in keratinocytes in a synergistic
manner
To assess the relevance of the upregulation of iNOS and NO
production observed in keratinocytes upon exposure to
recombinant IFN-g and TNF-a, we tested the effect of
activated T cells and relevant cytokines therein on iNOS
expression and NO production.
The median levels of IFN-g and TNF-a in conditioned
medium from nonstimulated PBMCs were 80 pg ml 1 ±40
and 20 pg ml1 ±40, respectively, whereas anti-CD3 stimu-
lation of PBMCs resulted in raised levels of IFN-g and TNF-a
(Table 1). We then assessed the importance of IFN-g and
TNF-a derived from CD3-activated PBMCs on keratinocyte
iNOS and NO induction, as well as FasL expression, using
neutralizing antibodies or molecules against these cytokines.
Two different anti-IFN-g antibodies significantly decreased
the induction of keratinocyte iNOS and FasL expression
(Figure 5a and b), as well as NO production (Figure 5b).
Soluble TNF-receptor:Fc fusion protein also had an inhibitory
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effect on iNOS expression and NO production, although to a
lesser extent. The control ectodysplasin A receptor:Fc fusion
protein had no effect, excluding an unspecific effect of the
Fc:fusion moiety. Maximal inhibition of NO production
was observed when IFN-g and TNF-a were inhibited simulta-
neously (Figures 5a and b). Importantly, the addition of
anti-IFNg and TNF-receptor:Fc to the conditioned medium
exhibited a significant protective effect on keratinocytes,
resulting in increased viability of keratinocytes exposed to
conditioned medium from activated PBMCs (Figure 5c). Alto-
gether, these results suggest that IFN-g and TNF-a secreted by
activated T cells have a synergistic effect on iNOS induction
and apoptosis in keratinocytes.
DISCUSSION
Here, we describe the existence of a potential molecular link
between cytokines secreted by drug-specific T cells in TEN
and NO-dependent FasL upregulation in keratinocytes. From
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our in vitro experiments, we could show that T-cell clones
from a TEN patient, similar to anti-CD3-activated T cells,
secrete high levels of IFN-g and TNF-a, and that these
cytokines are necessary and sufficient to induce subsequent
upregulation of keratinocyte iNOS expression and NO
production. We also demonstrate that large amounts of
NO generated by NO donors induced a direct increase of
FasL expression on keratinocytes and in reconstituted
epidermal equivalents. The relevance of our data is supported
by the observation of high levels iNOS expression in kerati-
nocytes within lesional skin of TEN patients (Lerner et al.,
2000), by the proapoptotic role of NO reported in other
cell types (Lee et al., 2006) and by the observation that
NO-releasing topical ointments induce keratinocyte apoptosis
(Ormerod et al., 1999).
We propose that an increased sensitivity to FasL, due to
iNOS-mediated NO production, may occur in TEN. Indeed,
a direct oxidative stress in keratinocytes is believed to be
necessary to sensitize them to apoptosis (Paquet and Pierard,
2007). The necessity for a concomitant oxidative stress
priming keratinocytes to undergo apoptosis after T-cell
activation may explain why strong T-cell activators such as
viruses, vaccines, imiquimod, or IFN-g injection themselves
rarely induce significant keratinocyte necrolysis.
As the cytokine levels measured in TEN blister fluids are
either lower or in the same range, that is, mean TNF-a
200 pg ml 1 (range 0–872 pg ml1) and mean IFN-g
547 pg ml 1 (range 22–1,889 pg ml 1) (Rhodes et al., 1999;
Nassif et al., 2004b; Quaglino et al., 2007; Gandhi et al.,
2008), compared with the ones detected in conditioned
medium, one may also ask whether the concentration of
these cytokines in blister fluids reflects that in the intercellular
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(annexin-V /PI cells) of HEK cells exposed to conditioned medium from
activated PBMCs in the presence or absence of specific IFN-g and TNF-a
blockers (mean±SD, n¼ 3, *Po0.01). For all these experiments control
isotypes and ectodysplasin A receptor (EDAR):Fc were used as irrelevant
controls.
Table 1. Cytokine secretion from PBMCs stimulated
with CD3 antibody and T-cell clones stimulated with
phenytoin
PBMC IFN-c TNF-a IL-10 IL-5 IL-4 IL-2
Batch 1 4,989.6 920.9 52.2 2,771.5 3.8 4.2
Batch 2 4,983.5 1,427 146 4,371.4 ND ND
TCC ST
1 571.78 49.82 ND 4,146.08 1,110.90 ND
2 6,119.76 226.11 ND 4,259.29 1,374.13 270.05
3 6,572.00 284.12 ND 4,776.69 628.66 316.34
4 9,915.38 114.86 ND 4,224.60 1,280.15 ND
5 9,192.94 29.40 ND 4,512.94 51.49 ND
6 9,952.42 516.45 ND 4,603.81 1,842.19 202.03
7 708.09 77.86 ND 3,940.36 3,081.50 61.51
8 1,093.78 32.32 ND 3,507.88 1,204.69 ND
9 410,000 682.81 ND 4,622.01 ND 169.44
10 1,391.47 206.25 ND 3,106.16 45,000 1,416.85
Abbreviations: ND, not detectable; PBMC, peripheral blood mononuclear
cells; TCC ST, stimulated T-cell clones; TNF-a, tumor necrosis factor-a.
Cytokine levels expressed as pg ml 1 above control.
4 implies beyond accurate detectable range of test.
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milieu between keratinocytes. To resolve the above questions,
an appropriate in vivo model will be required that can be
specifically manipulated at a molecular level. Unfortunately,
such a model of TEN does not exist to date.
Recent scientific work suggests that other signaling
pathways are involved in the onset of keratinocyte cell death
in TEN. Examples include the activation of CD40L, which
may, however, only be indicative of T-cell activation
(Caproni et al., 2006) and, more interestingly, the crucial
discovery that granulysin is upregulated in TEN and likely
to have a direct role in the activation of keratinocyte death
(Chung et al., 2008). FasL- and granulysin-mediated apoptosis
may be not mutually exclusive mechanisms in massive
keratinocyte death and may occur either sequentially or
simultaneously in TEN. Elevated soluble FasL levels have
been reported in the serum of patients suffering from TEN
(Pasutto et al., 2007; Stur et al., 2007). However, FasL has
been shown to be unable to induce apoptosis in its soluble
monomeric form (Schneider et al., 1998). Hence, it is very
likely that membrane-bound FasL, expressed by keratinocytes
upon cytokine exposure, induces apoptosis of Fas-expressing
surrounding keratinocytes.
The proposed involvement of IFN-g, TNF-a, and NO in
addition to FasL and granulysin in TEN pathogenesis has
therapeutic implications. Although it might be valuable to
block the final common pathway of FasL/Fas interaction, the
main method is with intravenous immunoglobulin, which
unfortunately varies in its content of anti-Fas antibodies and
therefore potentially in its reliability as a therapy at a given
dose. Therefore, targeting upstream events, in particular TNF-a
and possibly IFN-g, may be a possible alternative. TNF-a
blockade with infliximab or etanercept has been reported to
act favorably in isolated case reports of TEN (Hunger et al.,
2005; Wojtkiewicz et al., 2008; Gubinelli et al., 2009).
Blockade of IFN-g is less established, but intravenous
immunoglobulin that have shown therapeutic effect in
certain case series (Prins et al., 2003; Trent et al., 2003;
French, 2006) are known to also have an inhibitory effect on
IFN-g (Park-Min et al., 2007). The approach of blocking iNOS
is more difficult, and it is curious that glucocorticoids, which
are potent inhibitors of iNOS (Gilbert and Herschman, 1993),
are less efficient in arresting the epidermal necrolysis. The
simultaneous targeting of FasL and granulysin should also be
considered. A systematic approach analyzing the clinical
outcomes resulting from blocking the individual mediators
has the possibility not only of identifying the most effective
therapeutic approach but also of defining the critical
pathogenetic mediator.
MATERIALS AND METHODS
Cell culture and epidermal equivalents
Secondary cultures of HEK, primary isolated from foreskin (Limat
et al., 1989), were grown in Epilife medium containing supplement
(Cascade Biologics, Portland, OR). HaCaT cells (ATCC, Rockville,
MD) were grown in DMEM supplemented with 10% fetal calf serum
and antibiotics (Gibco BRL, Life Technologies, Paisley, UK).
The EpiDerm in vitro model of human epidermis was kindly
provided by MatTek Corporation (Ashland, MD). EpiDerm was
equilibrated on solid agar at 4 1C, for at least 1 hour in EPI-100-ASY
medium (MatTek Corporation) before experiments.
NO donors
The long half-lived NO donors SNP at 0.5 mM concentration and
DETA NONOate (NOC18) (Calbiochem, La Jolla, CA) were used. The
different chemical structures of SNP and NOC18 help ensure that
NO-donor effects result from NO release and not from the chemicals
themselves or byproducts other than NO.
Detection of FasL expression, NO production, and apoptosis by
FACS analysis
Cell-surface FasL expression was analyzed using G247-4 antibody
(Pharmingen, San Diego, CA) and MOPC-21 isotype control (Becton
Dickinson, San Jose, CA) mixed with the metalloprotease inhibitor
KB8301 (Pharmingen), followed by incubation with anti-mouse Alexa
488–conjugated IgG (Molecular Probes, Eugene, OR). Apoptosis was
quantified by flow cytometry using Annexin-V-FITC (Pharmingen) and
NO production using DAF–FM–DA (Alexis, San Diego, CA).
Fas signaling inhibition
HaCaT cells were exposed to 5 mM SNP or NOC18 during 8 hours for
apoptosis detection. Thirty minutes before addition of NO donors, the
caspase inhibitor ZVAD (50mM) and Fas inhibitor Fas:Fc (30mg ml 1,
Alexis) were added to the culture medium.
EpiDerm was incubated for 24 hours with medium containing or
not containing apoptotic inhibitors and controls: Fas:Fc 200mg ml 1,
control-Fc 200mg ml 1, Fas:Comp 50mg ml 1, caspase-8 inhibitor
(Z-IETD-FMK) 50mM, and its control Z-FA-FMK (50mM, Alexis, San
Diego, CA) or intravenous immunoglobulin 200mg ml 1. Incubation
was pursued for 24 hours by adding new medium containing or not
containing 7.5 mM-NOC18 plus apoptotic inhibitors when necessary.
Immunohistochemistry
EpiDerm cryosections were treated with N20 anti-FasL rabbit poly-
clonal antibody (1/2000, Santa Cruz Biotechnology, Santa Cruz, CA)
followed by anti-rabbit biotinylated antibody (1/250, Dako Diagno-
stics AG, Zug, Switzerland). We detected biotinylated antibody
complexes by using the streptavidin ABC complex/HRP kit (Dako)
and revealed peroxidase using AEC solution with H2O2. Harris
Hematoxylin was used as a counterstain. For negative controls, we
used mouse IgG and rat IgM, respectively.
Reverse transcriptase–PCR (RT–PCR)
RT–PCR and amplification were performed from total RNA using the
Qiagen kit (Qiagen AG, Basel, Switzerland). iNOS RT–PCR (30 cycles)
was carried out using the following primers: 50-AGCATGTAC
CCTCGGTTCTG-30 and 50-GGGGATCTGAATGTGCTGTT-30 and for
b-actin (30 cycles) 50-TGA TGG ACT CCG GTG ACG G-30 and
50-TGT CAC GCA CGA TTT CCC GC-30. iNOS (201 bp) and b-actin
(179 bp) PCR products were analyzed by 2% agarose gel electrophor-
esis. The relative quantities of iNOS PCR products were determined by
densitometric analysis and normalized with the one of b-actin.
Quantitative RT–PCR
Quantitative RT–PCR was performed with the SYBR-green on ABI
prism 7700 sequence detection system (Applied Biosystems, Foster
City, CA). For each gene the results were normalized to ribosomal
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protein L27 (RPL27) and given as 2DDCt values normalized to
untreated human keratinocytes or healthy human skin samples. The
results are represented as mean±standard deviation of three inde-
pendent experiments. The detailed information about oligonucleotide
primers and conditions used are available upon request.
Cytokine stimulation, cytokine blockade, and NO inhibition
HEK cells were incubated for 24–72 hours in Epilife medium contain-
ing 20ng ml 1 IFN-g, 75ngml 1 TNF-a, and 500pgml 1 IL-1b before
iNOS mRNA expression analysis. For NO cell production analysis,
cells were incubated with cytokines overnight, and then we replaced it
with new medium and measured NO production 24–72 hours after the
starting point of cytokine treatment. When necessary, iNOS inhibitor
L-NMMA (3mM) was added in Epilife 2hours before cytokine treatment.
For IFN-g blockade, monoclonal anti-human IFN-g antibodies (Sigma
(Buchs, Switzerland), clone 25,718.11 or R & D systems (Abingdon,
UK) clone 25,718) were added to PBMC supernatants before their
application on HEK cells. Isotype-matched antibodies (IgG2a, Santa
Cruz sc-53758) were used as controls. TNF-a was blocked with
TNFR:Fc (50mg ml 1), (Enzo Life Sciences, Lausen, Switzerland) and
compared with ectodysplasin A receptor:Fc (Enzo Life Sciences).
PBMC-conditioned medium
Human PBMCs were stimulated for 72 hours with 0.1mg ml 1 anti-
CD3 (OKT3, ATCC) in RPMI supplemented with 10% fetal calf serum
and antibiotics. HEK cells were incubated with medium from
nonactivated or CD3-activated PBMCs during 4–24 hours for iNOS
mRNA analysis and 24 hours for apoptosis detection. For NO produc-
tion analysis, cells were incubated with conditioned medium over-
night, and then we replaced it with new medium and measured NO
production 24 hours after the starting point of conditioned medium
treatment. When necessary, iNOS inhibitors L-NMMA (3 mM) and
1,400W (2mM) were added in Epilife 2 hours before treatment with
conditioned medium. When necessary, apoptotic inhibitors and
controls (Ac-DEVD-CHO 100mM, ZVAD 50mM, Z-IETD-FMK 50mM,
and Z-FA-FMK 50mM (Alexis, San Diego, CA)) or anti-Fas antibody
ZB4 (100 ng ml 1) and MOPC-31 control (100 ng ml 1) were added
1 hour before treatment with conditioned medium.
T-cell clone medium
Ten T-cell clones were isolated from blister fluid from a patient
suffering from phenytoin-induced TEN. Freshly isolated cells con-
tained in blister fluid from a patient suffering from TEN were grown
in vitro in the presence of irradiated (3,000 rads) PBMCs, 20 UI ml 1
IL-2, and 50 mg ml 1 phenytoin. After 21 days, cells were cloned by
limiting dilution with irradiated PBMCs, 20 UI ml 1 IL-2, and
50mg ml 1 phenytoin in 96 round-bottom plates. T cells were
restimulated every 14th day. Individual clones were then expanded.
After expansion, culture supernatants were collected from clones
undergoing a final restimulation with phenytoin or vehicle.
HEK cells were then exposed to conditioned medium of phenytoin
or vehicle-activated T-cell clones during 24 hours. We then analyzed
iNOS mRNA expression or NO presence, FasL expression, and
apoptosis by FACS as described above.
Statistical analysis
Groups were compared using one-tailed Student’s or Aspin–Welch’s
t-tests.
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